r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer

Neoadjuvant Etoposide, Ifosfamide, and Cisplatin Followed by Concomitant Thoracic Radiotherapy and Continuous Cisplatin Infusion in Stage IIIb Non-small Cell Lung Cancer

“…19,20 We have previously published two phase II studies using the present dosage and schedule of VIP combination in NSCLC. 6,19 Taken as a whole, the three studies (including the one presented herein) consisted of 97 NSCLC patients. This population was selected owing to its relatively good prognosis among other subgroups with unresectable NSCLC inasmuch as locally advanced stages were predominant (stage IIIa: 37%; stage IIIb: 54%; and stage IV: 9%).…”

“…We recently published the feasability of recombinant human methionyl granulocyte colony stimulating factor (r-metHuG-CSF) as an adjunct to etoposide, ifosfamide, cisplatin (VIP) regimen in 20 patients with locally advanced or metastatic NSCLC. 6 In the present study, we investigated the applicability and safety of this regimen as a neoadjuvant chemotherapy to a concomitant thoracic radiotherapy and cisplatin continuous infusion.…”

Neoadjuvant Etoposide, Ifosfamide, and Cisplatin Followed by Concomitant Thoracic Radiotherapy and Continuous Cisplatin Infusion in Stage IIIb Non-small Cell Lung Cancer

“…19,20 We have previously published two phase II studies using the present dosage and schedule of VIP combination in NSCLC. 6,19 Taken as a whole, the three studies (including the one presented herein) consisted of 97 NSCLC patients. This population was selected owing to its relatively good prognosis among other subgroups with unresectable NSCLC inasmuch as locally advanced stages were predominant (stage IIIa: 37%; stage IIIb: 54%; and stage IV: 9%).…”

“…We recently published the feasability of recombinant human methionyl granulocyte colony stimulating factor (r-metHuG-CSF) as an adjunct to etoposide, ifosfamide, cisplatin (VIP) regimen in 20 patients with locally advanced or metastatic NSCLC. 6 In the present study, we investigated the applicability and safety of this regimen as a neoadjuvant chemotherapy to a concomitant thoracic radiotherapy and cisplatin continuous infusion.…”

Neoadjuvant Etoposide, Ifosfamide, and Cisplatin Followed by Concomitant Thoracic Radiotherapy and Continuous Cisplatin Infusion in Stage IIIb Non-small Cell Lung Cancer

“…19,20 We have previously published two phase II studies using the present dosage and schedule of VIP combination in NSCLC. 6,19 Taken as a whole, the three studies (including the one presented herein) consisted of 97 NSCLC patients. This population was selected owing to its relatively good prognosis among other subgroups with unresectable NSCLC inasmuch as locally advanced stages were predominant (stage IIIa: 37%; stage IIIb: 54%; and stage IV: 9%).…”

“…We recently published the feasability of recombinant human methionyl granulocyte colony stimulating factor (r-metHuG-CSF) as an adjunct to etoposide, ifosfamide, cisplatin (VIP) regimen in 20 patients with locally advanced or metastatic NSCLC. 6 In the present study, we investigated the applicability and safety of this regimen as a neoadjuvant chemotherapy to a concomitant thoracic radiotherapy and cisplatin continuous infusion.…”

Neoadjuvant Etoposide, Ifosfamide, and Cisplatin Followed by Concomitant Thoracic Radiotherapy and Continuous Cisplatin Infusion in Stage IIIb Non-small Cell Lung Cancer

“…19,20 We have previously published two phase II studies using the present dosage and schedule of VIP combination in NSCLC. 6,19 Taken as a whole, the three studies (including the one presented herein) consisted of 97 NSCLC patients. This population was selected owing to its relatively good prognosis among other subgroups with unresectable NSCLC inasmuch as locally advanced stages were predominant (stage IIIa: 37%; stage IIIb: 54%; and stage IV: 9%).…”

“…We recently published the feasability of recombinant human methionyl granulocyte colony stimulating factor (r-metHuG-CSF) as an adjunct to etoposide, ifosfamide, cisplatin (VIP) regimen in 20 patients with locally advanced or metastatic NSCLC. 6 In the present study, we investigated the applicability and safety of this regimen as a neoadjuvant chemotherapy to a concomitant thoracic radiotherapy and cisplatin continuous infusion.…”